Amgen, Inc.’s Otezla was the only branded oral drug available for use in psoriasis patients after topical medicines but before biologics for the inflammatory skin condition until Bristol Myers Squibb Company’s Sotyktu (deucravacitinib) entered the field with US Food and Drug Administration approval in September. Now the companies have their first full quarter of combat behind them and managements’ comments show where each has taken hits in the battle for market share.
Amgen’s EVP of global commercial operations Murdo Gordon said during the company’s 31 January fourth quarter sales and earnings call that Amgen remains confident in Otezla’s sales growth, especially with FDA approval for mild-to-moderate psoriasis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?